Amarin Corp Plc (AMRN)

[jessellivermore]

HK...

Yes...The lipid world was not so clear and unified as to the effects of EPA vs DHA as Judge Du fantasizes..There were a number of studies and a number of differing opinions. These situations are ripe for "Cherry Picking"...The old Meta Analysis problem..

Du's judgement is based on nothing more than her pre determined opinion and is flawed...The fact Vascepa (EPA) not only worked to lower CVD event risk, but worked so well was a total shock to the lipidologists, and cardiologists is by far and away the most important thing..Du and her opinion are twisted...She should have been present at the 2018 AHA meeting where the R-I results were presented. The presentation by Bhatt got a standing ovation...And the cardiologists were polled electronically on their cell phones as how they thought the R-I trial would effect their practices. Before the presentation less than ten percent of the Cards said they would treat their patients at risk with EPA and statins,,After the presentation the doctors who planned to use Vascepa was over 90%...

":>) JL